This article is more than 5 years old. Information may no longer be current.
Earlier prediabetes screenings yielded economic benefits
Click Here to Manage Email Alerts
SAN FRANCISCO — Researchers observed significant economic benefits associated with lifestyle intervention, highlighting the importance of screening, early detection and treatment for prediabetes, according to data presented at the American Diabetes Association’s 74th Scientific Sessions.
“In 2010, an estimated 24.4 million adults with prediabetes met USPSTF screening criteria; 33.9 million adults with prediabetes met ADA criteria,” Timothy M. Dall, MS, health economist and managing director of the IHS Life Sciences Consulting Practice in Washington, D.C., said during a presentation here. “The purpose of this study was to illustrate the potential clinical and economic benefits of screening for and treating prediabetes with lifestyle intervention to prevent or delay onset of type 2 diabetes and sequelae.”
In their study, Dall and colleagues used a Markov model using Monte Carlo simulation to model disease onset among a nationally represented sample (n=3,700) of adults with prediabetes from the 2003-2010 National Health and Nutrition Examination Survey, according to data.
They utilized the UK Prospective Diabetes Study, Framingham Heart Study and other studies to predict equations for diabetes and sequelae. They also considered the 10-year follow-up results from the lifestyle and control arms of the Diabetes Prevention Program (DPP).
Data suggested that meeting DPP results would reduce diabetes onset by 41%, congestive heart failure by 33%, and ischemic heart disease by 22%, with substantial reductions in other morbidities, after 10 years.
Economic, per-person benefits over the course of 10 years included $6,300 in medical savings and $17,800 in total economic benefits; 20% lower mortality risk, and 0.3 additional quality-adjusted-life-years, according to data.
“Lifestyle intervention among the prediabetes population is cost-effective,” Dall said. — by Samantha Costa
Disclosure: Dall reports consultancy for Novo Nordisk.
For more information: Dall TM. Abstract 20-OR. Presented at: American Diabetes Association’s 74th Scientific Sessions; June 13-17, 2014; San Francisco.